<DOC>
	<DOCNO>NCT02705105</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability determine maximum tolerate dose ( MTD ) recommend fix dose combination mogamulizumab nivolumab subject locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Study Mogamulizumab + Nivolumab Subjects w/Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>This multicenter , Phase 1/2 open-label , dose-finding cohort expansion study anti-CCR4 antibody mogamulizumab combination therapy anti-PD-1 antibody nivolumab adult subject locally advance metastatic solid tumor . Phase 1 identify maximum tolerate dose ( MTD ) high protocol-defined dose absence exceed MTD , combination regimen mogamulizumab nivolumab subject . Phase 1 enroll 12 subject . Phase 2 explore safety , efficacy anti-tumor activity high tolerate dose combination regimen . Phase 2 enroll 184 subject .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Subject age 18 year old ; Subject must histologically cytologically confirm solid tumor ; Subject must locally advance metastatic solid tumor ; Subjects progress intolerant standard treatment regimen refuse standard treatment , adequate standard therapy exist . Subjects evaluable lesion per guideline Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 ; If subject woman childbearing potential man sexually active woman childbearing potential , subject agrees use adequate contraception sign ICF , duration study participation ; 23 week last dose IMP woman 31 week last dose IMP men ; Subjects adequate hematological , renal , hepatic respiratory function define . The subject willing undergo tumor biopsy Screening period , tumor inaccessible biopsy , archive tumor material must available submission ; Subjects voluntarily sign dated Institutional Review Board approve inform consent form accordance regulatory institutional guideline . Exclusion Criteria Female subject pregnant breastfeeding , subject expect conceive father child study ; Subjects uncontrolled significant intercurrent illness . Subjects psychiatric illness/social situation opinion investigator would limit compliance study requirement ; Subject primary central nervous system ( CNS ) tumor know CNS metastasis and/or history CNS metastases and/or carcinomatous meningitis ; Exception : Subjects eligible CNS metastases adequately treated subject neurologically return baseline ( except residual sign symptom related CNS treatment ) least 4 week prior enrollment . In addition , subject must corticosteroids 4 week prior enrollment . Subject receive prior therapy cancer major surgery within 28 day , 42 day nitrosourea mitomycin C , prior Cycle 1 Day 1 , 14 day tamoxifen ; Subject receive radiotherapy radiosurgery within 14 day prior Cycle 1 Day 1 ; Subject previously treat antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody antibody drug specifically target Tcell costimulation checkpoint pathway ; Subject previously treat mogamulizumab ; Subject history allergy hypersensitivity study drug component ; Subject receive live , attenuated vaccine within 28 day prior Cycle 1 Day 1 ; Subject history organ transplant allogeneic bone marrow transplant ; Subject unresolved toxicity Grade &gt; 1 previous anticancer therapy Subject use immunosuppressive medication within 14 day Cycle 1 Day 1 . Subjects know active autoimmune disease history autoimmune disease may affect vital organ function require immune suppressive treatment include systemic corticosteroid ; Subjects history toxic epidermal necrolysis StevensJohnson syndrome ; Subjects history inflammatory bowel disease , Crohn 's disease , ulcerative colitis , Wegener 's granulomatosis ; Subject primary acquire immunodeficiency know history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ; Subject test positive hepatitis B surface antigen ( HBVsAg ) hepatitis C RNA indicate acute chronic infection except subject hepatocellular carcinoma ; Subject another active malignancy require concurrent intervention ; Subject receive investigational agent ; Subject another condition , opinion Investigator and/or Sponsor , would interfere evaluation IMP interpretation subject safety study result ; Subject history pneumonitis interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>KW-0761</keyword>
	<keyword>ONO-4538/BMS-936558</keyword>
	<keyword>Anti-tumor</keyword>
	<keyword>Mogamulizumab</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>Oncology</keyword>
</DOC>